OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Cortese on Methods for Evaluating immunologic Changes With Venetoclax in CLL

April 11th 2025

Matthew Cortese, MD, MPH, discusses the methods used to produce a comprehensive map of immune changes that occur with venetoclax treatment in CLL.

Dr van Meerten on the Optimal Use of Brexu-Cel in BTK Inhibitor–Naive MCL

April 11th 2025

Tom van Meerten, MD, PhD, outlines select patient subgroups with BTK inhibitor–naive relapsed/refractory MCL who may benefit from treatment with brexu-cel.

Dr He on the FDA Approval of Nivolumab Plus Ipilimumab for Unresectable/Metastatic HCC

April 11th 2025

Aiwu Ruth He, MD, PhD, discusses the significance of data from the CheckMate 9DW trial evaluating frontline nivolumab plus ipilimumab in metastatic HCC.

Dr Saxena on the Evolving Utility of Targeted Therapies for ALK+ NSCLC

April 11th 2025

Ashish Saxena, MD, PhD, discusses the evolving utility of targeted therapies for ALK-positive non–small cell lung cancer.

Dr Lopetegui-Lia on Adjuvant Therapy for Early-Stage TNBC With Residual Disease

April 11th 2025

Nerea Lopetegui-Lia, MD, discusses treatment options for patients with chemotherapy-pretreated early-stage high-risk TNBC with residual disease at surgery.

Dr Tarantino on the Evolving Role of Anthracycline- and Taxane-Based Regimens in HER2+ Breast Cancer

April 11th 2025

Paolo Tarantino, MD, discusses the evolving role of anthracycline- and taxane-based regimens in HER2-positive breast cancer.

Dr Somaiah on Overcoming Challenges to Multidisciplinary Approaches in Sarcoma

April 11th 2025

Neeta Somaiah, MD, details challenges that are associated with pathology diagnosis, NGS, and early opinions for patients with sarcomas.

Aguilar-Clancy on the Importance of Individualized Nutritional Support as a Component of Oncology Care

April 11th 2025

Claudia Aguilar Clancy, FNP-C, AOCNP, discusses the importance of individualized nutritional support as a component of oncology care.

Dr Kozek on Oncology Nurses’ Perceived Difficulties in Providing Palliative Care to Adult Patients

April 11th 2025

Caroline Kozek, DNP, RN, AGNP-C, OCN, discusses a study assessing oncology nurses’ perceived difficulties in providing palliative care to adult patients.

Dr Mahon on the Importance of Integrating Genomic Science Into Oncology Practice

April 10th 2025

Suzanne Mahon DNS, RN, AOCN, AGN-BC, FAAN, discusses the importance of integrating genomic science into oncology practice.

Dr Andorsky on Molecular Responses With Second-Line Asciminib in CP-CML

April 10th 2025

David J. Andorsky, MD, discusses molecular responses achieved with asciminib dose escalation in patients with CP-CML who had received 1 prior TKI.

Dr Hamilton on Treatment Selection After Progression on Frontline CDK4/6 Inhibition in HR+ Breast Cancer

April 10th 2025

Erika P. Hamilton, MD, discusses how mutational profiles inform the management of HR-positive breast cancer after progression on a prior CDK4/6 inhibitor.

Dr Ahmed on the Rationale for Evaluating NTKR-255 After CAR T-Cell Therapy in R/R LBCL

April 10th 2025

Sairah Ahmed, MD, explains the rationale for evaluating NTKR-255 after CAR T-cell therapy in relapsed/refractory large B-cell lymphoma.

Dr Lee on the Role of Integrative Medicine in Oncology Care

April 10th 2025

Richard Lee, MD, FASCO, discusses the role of integrative medicine in oncology care.

Dr Rampal on Personalizing Treatment Strategies for Patients With Myelofibrosis

April 10th 2025

Raajit Rampal, MD, discusses typical clinical applications of the 4 FDA-approved JAK inhibitors for the treatment of patients with myelofibrosis.

Dr Grisham on the Efficacy/Tolerability of Avutometinib Plus Defactinib in KRAS+ Serous Ovarian Cancer

April 10th 2025

Rachel N. Grisham, MD, discusses efficacy and tolerability data from the phase 2 ENGOT-OV60/GOG-3052/RAMP 201 subgroup analysis.

Dr Dholaria on the Rationale for Investigating P-BCMA-ALLO1 in R/R Myeloma

April 10th 2025

Bhagirathbhai Dholaria, MBBS, discusses the rationale and evolving investigation of P-BCMA-ALLO1 in patients with relapsed/refractory multiple myeloma.

Dr Bando on Safety of TAS-102 in MRD+ Resected CRC

April 9th 2025

Hideaki Bando, MD, PhD, discusses the safety of trifluridine/tipiracil in patients with MRD following resection of CRC.

Dr Escobar on CDK4/6 Inhibitor Selection in HR+ Metastatic Breast Cancer

April 9th 2025

Mauricio Escobar, MD, discusses CDK4/6 inhibitor selection based on retrospective real-world analyses in HR-positive metastatic breast cancer.

Dr Mateos on Ongoing Research With Cilta-Cel in Newly Diagnosed Multiple Myeloma

April 9th 2025

María-Victoria Mateos, MD, PhD, discusses next steps for evaluating the role of cilta-cel in lenalidomide-refractory and other multiple myeloma subtypes.